Alsevalimab is under evaluation as an experimental medicinal antibody targeting B7-H4 protein. This therapy demonstrates early effectiveness in various malignant diseases by blocking B7-H4 protein's function in neoplastic growth and host evasion. Present patient trials seek to determine the antibody's safety and therapeutic advantage for individual